SCHEMBL302059

SCHEMBL302059

O=C(c1cccc(N(Cc2ccccc2)S(=O)(=O)c2ccc(F)cc2)c1)N1CCOCC1

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 4/20 0.52
HPGD P15428 1/20 0.52
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
NR3C1 P04150 1/20 0.47
TSHR P16473 2/20 0.47
RECQL P46063 1/20 0.47
ESR1 P03372 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2189008 0.94 LMNA (0.49) LMNAMAPTKMT2AHPGDALDH1A1
SCHEMBL3377152 0.93 LMNA (0.60) LMNAKMT2AHPGDALDH1A1MEN1
SCHEMBL3377105 0.87 ALDH1A1 (0.49) LMNAKMT2AHPGDALDH1A1MEN1
SCHEMBL2213840 0.86 TSHR (0.53) LMNAMAPTKMT2AHPGDALDH1A1
SCHEMBL3374237 0.85 HPGD (0.52) LMNAKMT2AHPGDALDH1A1TSHR
SCHEMBL2192252 0.82 LMNA (0.71) LMNAMAPTKMT2AALDH1A1MEN1
SCHEMBL303280 0.82 ALDH1A1 (0.44) LMNAKMT2AHPGDALDH1A1L3MBTL1
SCHEMBL3377040 0.82 LMNA (0.48) LMNAKMT2AHPGDALDH1A1MEN1
SCHEMBL303740 0.81 LMNA (0.47) LMNAKMT2AHPGDALDH1A1MEN1
SCHEMBL3379849 0.79 MAPT (0.59) LMNAMAPTKMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US claimed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US claimed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US claimed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US claimed
JP-2012500836-A 2012-01-12 JP claimed
EP-2342177-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-07-13 EP claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023448-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885MAPT 2884/4885KMT2A 386/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 LMNA 2145/4885MAPT 4874/4885KMT2A 1511/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 LMNA 1619/4885MAPT 2884/4885KMT2A 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.